John C. VanRens

Development of Orally Bioavailable Bicyclic Pyrazolones as Inhibitors of Tumor Necrosis Factor-α Production

Michael P. Clark, Steven K. Laughlin, Matthew J. Laufersweiler et al. · Journal of Medicinal Chemistry · 2004 · 130 citations · Full text

The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck)

M. Sabat, John C. VanRens, Matthew J. Laufersweiler et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 68 citations · Full text

Medicinal Chemistry, Drug Target, Biochemistry +10

Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)

Michael P. Clark, Kelly M. George, Roger G. Bookland et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 55 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +8

The development of new triazole based inhibitors of tumor necrosis factor-α (TNF-α) production

Joshua S. Tullis, John C. VanRens, Michael G. Natchus et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 55 citations · Full text

Medicinal Chemistry, Anti-inflammatory, Tumor Necrosis +9

The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-α) production

Steven K. Laughlin, Michael P. Clark, Jane F. Djung et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 53 citations

Inflammation, Anti-inflammatory, Medicine +10